These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14722256)

  • 1. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.
    Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
    Mol Pharmacol; 2004 Jan; 65(1):235-43. PubMed ID: 14722256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
    Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
    Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.
    Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
    Cancer Res; 2003 Dec; 63(24):8600-5. PubMed ID: 14695170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
    Premkumar DR; Arnold B; Jane EP; Pollack IF
    Mol Carcinog; 2006 Jan; 45(1):47-59. PubMed ID: 16267832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
    Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
    Premkumar DR; Arnold B; Pollack IF
    Mol Carcinog; 2006 May; 45(5):288-301. PubMed ID: 16550610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines.
    Vasilevskaya IA; O'Dwyer PJ
    Biochem Pharmacol; 2005 Aug; 70(4):580-9. PubMed ID: 15993848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
    Jia W; Yu C; Rahmani M; Krystal G; Sausville EA; Dent P; Grant S
    Blood; 2003 Sep; 102(5):1824-32. PubMed ID: 12738674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
    Münster PN; Basso A; Solit D; Norton L; Rosen N
    Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway.
    Ohtsuka T; Buchsbaum D; Oliver P; Makhija S; Kimberly R; Zhou T
    Oncogene; 2003 Apr; 22(13):2034-44. PubMed ID: 12673208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
    Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
    Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
    Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
    Calabrese C; Frank A; Maclean K; Gilbertson R
    J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
    Münster PN; Marchion DC; Basso AD; Rosen N
    Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct mechanisms target stress and extracellular signal-activated kinase 1 and Jun N-terminal kinase during infection of macrophages with Salmonella.
    Procyk KJ; Rippo MR; Testi R; Hoffmann F; Parker PJ; Baccarini M
    J Immunol; 1999 Nov; 163(9):4924-30. PubMed ID: 10528195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells.
    Vasilevskaya IA; O'Dwyer PJ
    Cancer Res; 1999 Aug; 59(16):3935-40. PubMed ID: 10463587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
    Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
    Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
    Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
    Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.